In July 2023, in conjunction with the Company’s ongoing review of operations and the planned separation of its oncology business, the Company implemented a restructuring plan, which included the elimination of approximately 60 positions across the Company (the “Restructuring”). The Company recorded a charge of $6.0 million during the three and nine months ended September 30, 2023 as a result of the Restructuring, which consisted of one-time termination benefits for employee severance, benefits and related costs, all of which are expected to result in cash expenditures, and all of which are expected to be paid within 12 months of the Restructuring. During the three and nine months ended September 30, 2023, the Company recognized $4.5 million and $1.5 million of this expense in R&D expense and SG&A expense, respectively, in the accompanying condensed consolidated statements of comprehensive income (loss).

Activity related to the Restructuring during the three months ended September 30, 2023 was as follows:


(In thousands)
Balance, December 31, 2022	$	—
Restructuring charge		5,969
Amounts paid during the period:
Severance		(2,098	)
Benefits		(319	)
Outplacement services		(178	)
Balance, September 30, 2023	$	3,374

At September 30, 2023 and December 31, 2022, $3.4 million and none, respectively, of the restructuring accrual was included within “Accounts payable and accrued expenses” in the accompanying condensed consolidated balance sheets.